Aurobindo Pharma Ltd (Aurobindo) is a global pharmaceutical company that manufactures generic formulations, active pharmaceutical ingredients (APIs), and specialty products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Aurobindo is committed to enhancing patient impact through continuous research and development in pharmaceuticals. The company leverages advanced technologies, strategic partnerships, and a commitment to sustainability to drive excellence in research and development. It employs more than 1,500 scientists and analysts in product development. Key developments in FY2025 include receiving final approvals for numerous US ANDAs from the US FDA, filing of the first transdermal ANDA with a focus on product/process development. The R&D units of Aurobindo Pharma include Aurobindo Research Centre, Eugia Pharma, and Apitoria Pharma. The company has more than 30 state-of-the-art manufacturing and packaging facilities, which are approved by regulatory agencies such as the US FDA, EU GMP, South Africa-MCC, UK MHRA, Health Canada, Brazil ANVISA, and WHO. The company operates nine research facilities. The company has launched 33 products in the US market. As of March 2025, the company filed 861 ANDAs with the US FDA and 309 DMFs, and 18 API dossiers in Europe and 3,933 Formulation dossiers. The company has strategic collaborations with AI-based scientific companies and research collaborations focused on advanced informatics. In FY2025, the company spent INR16,220 million on its R&D activities, which as a percentage of revenue stood at 5.1%.